Delayed granulomatous eruption of the nose associated with ruxolitinib

The Janus kinase (JAK) signal transducer and activator of transcription pathway is a signaling mechanism that mediates cellular responses involved in inflammation.1 Ruxolitinib is a JAK1/2 inhibitor with US Food and Drug Administration approval for the treatment of myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease.2 JAK inhibitors are emerging as therapeutic agents in dermatology, with evidence of their efficacy shown in psoriasis, alopecia areata, vitiligo, and atopic dermatitis.